N-propionylated group B meningococcal polysaccharide glycoconjugate vaccine against group B meningococcal meningitis

International Journal of Infectious Diseases

Volumn 1, Issue 3, 1997, Pages 158-164

  Jennings, Harold J ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

conformational epitopes; glycoconjugate vaccine; group B Neisseria meningitidis; meningococcal vaccines; molecular mimicry N propionylated group B meningococcal polysaccharide

Indexed keywords

MENINGOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; BACTERICIDAL ACTIVITY; CONFERENCE PAPER; DRUG CONFORMATION; DRUG FORMULATION; DRUG POTENCY; EPIDEMIC MENINGITIS; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; NEISSERIA MENINGITIDIS; VACCINE PRODUCTION;

EID: 0030941062     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(97)90080-1     Document Type: Conference Paper

References (43)

1. Lepow ML, Goldschneider I, Gold M, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60:673-680.
2. Peltola H, Mäkelä PH, Käyhty H. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686-691
3. Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126:514-521.
4. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1012-1018.
5. Costantino P, Viti S, Podda A, et al. Development of phase 1 clinical testing of a conjugate vaccine against meningococcus A and meningococcus B. Vaccine 1992; 10:691-698.
6. Bartolini A, Norelli F, Ceccarini C, Rappuoli R, Constantino P. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine 1995; 13:463-470.
7. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983; 2:355-357.
8. Troy FA. Polysialylation: from bacteria to brains. Glycobiology 1992; 2:5-23.
9. Diaz-Romero J, Outschoorn IM. Current status of meningococcal group B vaccine candidates: capsular or non-capsular. Clin Microbiol Rev 1994; 7:559-575.
10. Poolman JT. Development of a meningoccal vaccine. Infect Agents Dis 1995; 4:13-28.
11. Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093-1096.
12. Cassio de Mordes J, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil Lancet 1992; 340:1074-1078.
13. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 1985; 7:504-510.
14. van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on class 1 outer membrane protein. Infect Immun 1992; 60:3156-3161.
15. Danve B, Lissolo L, Mignon M. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 1993; 11:1214-1220.
16. Lissoli L, Maitre-Wilmotte G, Dumas P, Mignon M, Danve B, Quentin-Millet MJ. Evaluation of transferrin-binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect Immun 1995; 63:884-890.
17. Mazarin V, Rokbi B, Quentin-Millet MJ. Diversity of the transferrin-binding protein Tbp2 of Neisseria meningitidis. Gene 1995; 158:145-146.
18. Verheul AFM, Snippe H, Poolman JT. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol Rev 1993; 57:34-49.
19. Kogan G, Uhrin D, Brisson J-R, Jennings HJ. Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Infect Immun (in press).
20. Verheul AF, Boons GJ, van der Marel GA, et al. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3, 7, 9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun 1991; 59:3566-3573
21. Jennings HJ, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986; 137:1708-1713
22. Jennings HJ. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. In: Cruse JM, Lewis RE, eds. Conjugate vaccines contributions to microbiology and immunology. Basel: Karger, 1989: 151-165.
23. Mandrell RE, Zollinger WD. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. J Immunol 1982; 129:2172-2178
24. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith ICP. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroup B and C with carbon-13 nuclear magnetic resonance. J Biol Chem 1975; 250:1926-1932.
25. Ando S, Yu RK. Isolation and characterization of two isomers of brain tetrasialogangliosides. J Biol Chem 1979; 254: 12,224-12,229.
26. Theodosis DT, Bonfanti L, Olive S, Rougon G, Poulain DA. Adhesion molecules and structural plasticity of the adult hypothalamo-neurohypophysical system. Psychoendocrin 1994; 19:455-462.
27. Orskov F, Orskov I, Sutton A. Form variation in Escherichia coli K1: determined by O-acetylation of the capsular polysaccharide. J Exp Med 1979; 149:669-685.
28. Frosch M, Gorgen I, Bitter-Süermann D. NZB mouse system for the production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A 1985; 82:1194-1198.
29. Rougon G, Dubois C, Buckley N, Magnani JL, Zollinger WD. A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM J Cell Biol 1986; 103:2429-2437.
30. Raff HV, Devereux D, Shuford W, Abbott-Brown D, Maloney G. Monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections. J Infect Dis 1988; 157:118-126
31. Kabat EA, Nickerson KG, Liao J, et al. A human monoclonal macroglobulin with specificity for α(2→8)-linked poly-N-acetylneuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which cross-reacts with nucleotides and with denatured DNA. J Exp Med 1986; 164:642-654.
32. Jennings HJ, Katzenellenbogen E, Lugowski C, Michon F, Roy R, Kasper DL. Structure, conformation, and immunology of sialic acid-containing polysaccharides of human pathogenic bacteria. Pure Appl Chem 1984; 56:893-905.
33. Jennings HJ, Roy R, Michon F. Determinant specificities of the groups B and C polysaccharides of Neisseria meningitidis. J Immunol 1985; 134:2651-2657.
34. Finne J, Mäkelä PH. Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. J Biol Chem 1985; 260:1265-1270.
35. Häyrinen J, Jennings H, Raff HV. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 1995; 171:1481-1490.
36. Kabat EA, Liao J, Osserman F, Gamian A, Michon F, Jennings HJ. The epitope association with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgM NOV J Exp Med 1988; 168:699-711.
37. Brisson J-R, Baumann H, Imberty A, Pérez S, Jennings HJ. Helical epitope of the group B meningococcal α(2→8)-linked sialic acid polysaccharide. Biochemistry 1992; 31: 4996-5004.
38. Baumann H, Brisson J-R, Michon F, Pon R, Jennings HJ. Comparison of the conformation of the epitope of α(2→8)-polysialic acid with its reduced and N-acyl derivatives. Biochemistry 1993; 32:4007-4013.
39. Evans SV, Sigurskjold BW, Jennings HJ, et al. Evidence for the extended helical nature of polysaccharide epitopes. The 2.8 Å resolution structure and thermodynamics of ligand binding of an antigen binding fragment specific of α(2→8)-polysialic acid. Biochemistry 1995; 34:6737-6744.
40. Ashton FE, Ryan JA, Michon F, Jennings HJ. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide Microb Pathog 1989; 6:455-458.
41. Jennings HJ, Gamian A, Ashton FE N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med 1987; 165: 1207-1211.
42. Jennings HJ, Gamian A, Michon F, Ashton FE. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1. J Immunol 1989; 142:3585-3591.
43. Nedelec J, Boucraut J, Garnier JM, Bernard D, Rougon G. Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. J Neuroimmunol 1990; 29:49-56.